Cornerstone Advisory LLC Has $3.57 Million Stake in Cencora, Inc. $COR

Cornerstone Advisory LLC lessened its stake in shares of Cencora, Inc. (NYSE:COR) by 23.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,407 shares of the company’s stock after selling 3,498 shares during the period. Cornerstone Advisory LLC’s holdings in Cencora were worth $3,565,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. Cloud Capital Management LLC bought a new stake in Cencora in the 3rd quarter valued at about $31,000. Vermillion & White Wealth Management Group LLC raised its stake in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after buying an additional 43 shares during the period. Westside Investment Management Inc. boosted its holdings in Cencora by 200.0% in the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after acquiring an additional 70 shares in the last quarter. Finally, Copia Wealth Management grew its stake in Cencora by 505.0% in the third quarter. Copia Wealth Management now owns 121 shares of the company’s stock valued at $38,000 after acquiring an additional 101 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. The trade was a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 15,220 shares of company stock worth $5,282,867. 0.38% of the stock is owned by company insiders.

Cencora Trading Up 2.7%

Shares of COR stock opened at $360.59 on Tuesday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The company has a market capitalization of $70.15 billion, a price-to-earnings ratio of 43.34, a PEG ratio of 1.66 and a beta of 0.68. Cencora, Inc. has a 52-week low of $237.71 and a 52-week high of $377.54. The company has a 50-day simple moving average of $347.97 and a two-hundred day simple moving average of $329.40.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.73 EPS. Research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s payout ratio is 28.85%.

Analyst Ratings Changes

A number of brokerages recently issued reports on COR. Mizuho increased their target price on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. UBS Group boosted their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. TD Cowen upped their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $399.00.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.